Role of Glial Cells in Retinal Ganglion Cell Death
Principal Investigator
Theresa Good, PhD
Texas A&M University Health Science Center
College Station, TX, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
G1999009
Summary
One hypothesis for how intraocular pressure leads to vision loss is that the cell damage is the result of increased mechanical forces. Dr. Good has proposed that glial cells within the retina contribute to optic nerve damage by producing toxic molecules (nitric oxide and glutamate). She is testing this hypothesis with an in vitro model of shear stress and strain, where retinal glial cells are deformed to mimic the stress that occurs in living eyes and then measuring the production of toxic compounds. Through these measurements, she hopes to identify factors that contribute to retinal ganglion cell death. The ultimate goal of this research is to develop new therapeutic approaches to treating glaucoma.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
National Glaucoma Research
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear